Elixirgen Therapeutics
Baltimore, MD · Biotechnology · 13 employees
Elixirgen Therapeutics is a biotechnology company advancing its controllable self-replicating RNA technology to develop therapies for a broad spectrum of diseases, including rare diseases, aging-related disorders, and cancer. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore.
Funding history
- Venture - Series Unknown — $4.0M — Nov 2025
- Seed — $3.6M — Apr 2025
- Seed — $600K — Feb 2025
- Venture - Series Unknown — $7.0M — Dec 2023
- Venture - Series Unknown — $5.0M — Sep 2022
Recent signals
- Nov 13, 2025: Raised $4.0M in Venture - Series Unknown
- Apr 09, 2025: Raised $3.6M in Seed
- Feb 12, 2025: Raised $600K in Seed
- Dec 01, 2023: Raised $7.0M in Venture - Series Unknown
- Sep 29, 2022: Raised $5.0M in Venture - Series Unknown
- Feb 18, 2021: Raised $4.2M in Venture - Series Unknown
- Aug 17, 2020: Raised $5.7M in Venture - Series Unknown
- Dec 02, 2019: Raised $5.7M in Venture - Series Unknown
See plans & pricing → Track Elixirgen Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.